CM
RAPP

Crestline Management’s Rapport Therapeutics RAPP Stock Holding History

Crestline Management’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-27,496
Closed -$488K – 694
2024
Q4 		$488K Buy
+27,496
New +$609K 0.02% 545

Other funds holding RAPP

TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Crestline Management's RAPP Position: Q1 2025 in Review

Crestline Management sold out of Rapport Therapeutics (RAPP) in Q1 2025, closing a stake of 27,496 shares — an estimated $488K sold.

Crestline Management first reported a position in RAPP in Q4 2024 and held it in 1 quarter. The position peaked at $488K in Q4 2024. 77 funds tracked by Wall St. Rank hold RAPP as of Q1 2025.

  • Crestline Management reported no remaining Rapport Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Crestline Management sold 27,496 Rapport Therapeutics shares in Q1 2025, an estimated $488K.
  • Crestline Management first reported a position in Rapport Therapeutics in Q4 2024 and held it in 1 quarter.
  • Crestline Management's Rapport Therapeutics position peaked at $488K in Q4 2024.
  • 77 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.